Drug intelligence / Profile preview

Lip-MSA-IL-2

Development stage: Preclinical
Lead developer: University of North Carolina at Charlotte
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intraperitoneal

Overview

Lip-MSA-IL-2 is a **liposome-encapsulated, mouse serum albumin-fused interleukin-2** engineered for enhanced half-life and immunostimulatory activity. IL-2 is a cytokine that stimulates proliferation of cytotoxic T cells and NK cells. Lip-MSA-IL-2 is designed to improve pharmacokinetics and local delivery, with the mouse serum albumin (MSA) fusion extending cytokine stability and liposome formulation providing targeted release. Preclinical evidence shows Lip-MSA-IL-2 as monotherapy increases immune cell infiltration and accelerates progression from PanIN to adenocarcinoma in some models, while combination therapy (with TAB004 antibody) produces slowed tumor progression, increased survival, increased myeloperoxidase, and altered serum cytokine profiles in spontaneous pancreatic cancer mouse models. The principal mechanism is **immune system activation via IL-2 receptor agonism**, resulting in expansion of cytotoxic effector cells and modulation of the tumor microenvironment[1][4].

Brand names: Lip-MSA-IL-2Lip-MSA-IL2Lip-MSA-IL 2
Other names: Lip-MSA-IL-2Lip-MSA-IL2Lip-MSA-IL 2

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on Lip-MSA-IL-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lip-MSA-IL-2.

Explore the full profile